GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...
GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...
WASHINGTON — Pharmaceutical industry giant GSK plans to depart the biotechnology industry’s largest trade group, the ...
GlobalData on MSN4d
GSK CEO addresses declining trust in vaccines following Trump re-electionGSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...
STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them.
GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback